✨ Free AI Report
G1 Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research G1 Therapeutics, Inc.
Company Research

G1 Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

G1 Therapeutics, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage commercial oncology biotech with promising revenue growth but capital constraints and profitability challenges requiring ongoing market validation. G1 Therapeutics demonstrates strong revenue growth trajectory and commercial execution in oncology, but faces profitability challenges with accumulated deficit and declining market valuation (trading at $7.15 vs. IPO price of $15.00).

What is G1 Therapeutics, Inc.'s industry? G1 Therapeutics, Inc. (g1therapeutics.com) operates in Oncology Drugs. AskCyborg classifies G1 Therapeutics, Inc. under Oncology Drugs in its company registry.

G1 Therapeutics is a commercial-stage oncology company headquartered in Research Triangle Park, NC. The company completed its initial public offering in May 2017, trading under ticker GTHX on the NASDAQ.

4/ 10Mixed

Cyborg Score thesis

Early-stage commercial oncology biotech with promising revenue growth but capital constraints and profitability challenges...

Read the full analyst-debate transcript →
Industry Oncology Drugs
2 named competitors
1 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 5, 2026
AI-Verified Research
30+ Page Report

Get the Latest G1 Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for G1 Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for G1 Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
G1 Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

G1 Therapeutics, Inc. Overview

Pro stress-test →

G1 Therapeutics is a commercial-stage oncology company headquartered in Research Triangle Park, NC. The company completed its initial public offering in May 2017, trading under ticker GTHX on the NASDAQ.

Strategic Profile

Pro stress-test →

As of June 2026, the company has a market capitalization of approximately $377 million. The company appears to be in growth phase, with total revenues of $82.5 million in 2023 compared to $51.3 million in 2022, representing 61% year-over-year growth.

Competitive Landscape

Pro stress-test →

G1 Therapeutics competes in the commercial-stage oncology therapeutics market against companies developing cell cycle checkpoint inhibitors and cancer treatment modalities. Specific competitive positioning requires additional visibility into pipeline programs and clinical trial results.

Industry Context

G1 Therapeutics, Inc. operates in Oncology Drugs.

Key facts

Founded: 2008 · Headquarters: Research Triangle Park, NC, US · Revenue: $82.5M (2023) · Market cap: $377M

What the analysts stress-tested

The top findings that survived the multi-agent debate for G1 Therapeutics, Inc..

  • Revenue growth accelerating: 61% YoY increase from 2022 to 2023 ($51M to $82.5M), demonstrating commercial traction
  • Capital constraints evident: Market cap ~$377M with accumulated deficit of $780M as of end-2023
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2026Stock trading at $7.15 per share on NASDAQ (GTHX ticker)
Get alerted when G1 Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Checkpoint inhibitors / Cancer therapeuticsOncology and inflammatory disease therapeutics→Cell cycle regulationCell cycle and checkpoint control therapeutics→

Compare G1 Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

G1 Therapeutics, Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about G1 Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare G1 Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did G1 Therapeutics, Inc. do this quarter?”
“Is G1 Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does G1 Therapeutics, Inc. do?+
G1 Therapeutics is a commercial-stage oncology company headquartered in Research Triangle Park, NC. The company completed its initial public offering in May 2017, trading under ticker GTHX on the NASDAQ.
What is G1 Therapeutics, Inc.'s Cyborg Score?+
G1 Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are G1 Therapeutics, Inc.'s main competitors?+
Named competitors include Checkpoint inhibitors / Cancer therapeutics, Cell cycle regulation. The full competitive landscape is in the AskCyborg report.
How can I get the full G1 Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the G1 Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track G1 Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.